Aestus Therapeutics Initiates Phase 2 Clinical Trial for Novel Neuropathic Pain Treatment

Aestus Therapeutics, Inc. (Aestus), announced today that it has initiated screening of patients for a clinical trial to evaluate the efficacy of its novel pain therapeutic, ATx08-001. This placebo-controlled, two-dose level study will test the efficacy of ATx08-001 in reducing the pain following an outbreak of shingles.

Aestus Therapeutics is located at the Commercialization Center for Innovative Technologies, a member of the New Jersey Business Incubation Network.

To view a full press release, click on the PDF link below.

Attachments:

Aestus Ph2 PHN press release FINAL 022311.pdf